Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes
Open Access
- 18 March 2016
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (8) , 1964-1969
Abstract
Objective: To measure variance in antiphospholipid antibody (aPL) levels during pregnancy and to determine if variation affects pregnancy outcomes.Methods: We used data from the PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study, a multicenter prospective study of pregnant women with aPL and/or systemic lupus erythematosus (SLE). Antiphospholipid antibodies were considered present if any of the following were positive: anticardiolipin (aCL), anti–β2‐glycoprotein I (anti‐β2GPI) titers ≥40 IgG phospholipid (GPL) or IgM phospholipid (MPL) units, and/or lupus anticoagulant (LAC). Antiphospholipid antibodies were measured every trimester and postpartum. Adverse pregnancy outcomes were defined as fetal/neonatal death, preterm delivery (2GPI remained high‐positive through pregnancy in 93% of patients during the second trimester, and in 85% of patients during the third trimester. IgM aPL titers were negative in the majority of patients and decreased modestly during pregnancy among patients who were positive. LAC frequency also decreased, but 75% of patients remained positive through the second trimester. Only 4% of patients with aPL at baseline did not have aPL in either the second or third trimesters. Changes in aPL levels or aPL status were not associated with adverse pregnancy outcomes. LAC was the only aPL associated with adverse pregnancy outcomes.Conclusion: The aPL in the cohort decreased marginally during pregnancy, and changes were not associated with pregnancy outcomes. Our results suggest that, among women with aPL and/or SLE, measuring aPL early in pregnancy is sufficient to assess risk. Repeat aPL testing through pregnancy is unnecessary.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (AR-49772)
This publication has 16 references indexed in Scilit:
- Predictors of Pregnancy Outcomes in Patients With LupusAnnals of Internal Medicine, 2015
- Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literatureAutoimmunity Reviews, 2015
- Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levelsJournal of Reproductive Immunology, 2012
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Longitudinal study of antinuclear and anticardiolipin antibodies in pregnant women with systemic lupus erythematosus and antiphospholipid syndromeRheumatology International, 2002
- Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal LossJournal of Experimental Medicine, 2002
- Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal andheparin-treated antiphospholipid syndrome pregnanciesLupus, 2002
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcomeAmerican Journal of Obstetrics and Gynecology, 1994
- Course of antiphospholipid antibodies in patients with primary antiphospholipid syndrome before, during and after pregnancy treated with low dose aspirin. Relationship of antibody levels to outcome in 7 patients.1992